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Summary
Background The reduction by a third of premature non-communicable disease (NCD) mortality by 2030 is the 
ambitious target of Sustainable Development Goal (SDG) 3.4. However, the indicator is narrowly defined, including 
only four major NCDs (cardiovascular diseases, cancer, diabetes, and chronic respiratory diseases) and only for people 
aged 30−70 years. This study focuses on premature avertable mortality from NCDs—premature deaths caused by 
NCDs that could be prevented through effective public policies and health interventions or amenable to high-quality 
health care—to assess trends at global, regional, and national levels using estimates from the Global Burden of 
Disease, Injuries, and Risk Factors Study (GBD) 2017.
Methods We reviewed existing lists of NCD causes of death that are either preventable through public health policies 
and interventions or amenable to health care to create a list of avertable NCD causes of death, which was mapped to the 
GBD cause list. We estimated age-standardised years of life lost (YLL) per 100 000 population due to premature avertable 
mortality from NCDs, avertable NCD cause clusters, and non-avertable NCD causes by sex, location, and year and 
reported their 95% uncertainty intervals (UIs). We examined trends in age-standardised YLL due to avertable and non-
avertable NCDs, assessed the progress of premature avertable mortality from NCDs in achieving SDG 3.4, and explored 
specific avertable NCD cause clusters that could make a substantial contribution to overall trends in premature mortality.
Findings Globally, premature avertable mortality from NCDs for both sexes combined declined –1·3% (95% UI 
–1·4 to –1·2) per year, from 12 855 years (11 809 to 14 051) in 1990 to 9008 years (8329 to 9756) in 2017. However, the 
absolute number of avertable NCD deaths increased 49·3% (95% UI 47·3 to 52·2) from 23·1 million (22·0–24·1) deaths 
in 1990 to 34·5 million (33·4 to 35·6) in 2017. Premature avertable mortality from NCDs reduced in every WHO region 
and in most countries and territories between 1990 and 2017. Despite these reductions, only the Western Pacific and 
European regions and 25 countries (most of which are high-income countries) are on track to achieve SDG target 3.4. 
Since 2017, there has been a global slowdown in the reduction of premature avertable mortality from NCDs. In 2017, 
high premature avertable mortality from NCDs was clustered in low-income and middle-income countries, mainly in the 
South-East Asia region, Eastern Mediterranean region, and African region. Most countries with large annual reductions 
in such mortality between 1990 and 2017 had achieved low levels of premature avertable mortality from NCDs by 2017. 
Some countries, the most populous examples being Afghanistan, the Central African Republic, Uzbekistan, Haiti, 
Mongolia, Turkmenistan, Pakistan, Ukraine, Laos, and Egypt, reported both an upward trend and high levels of premature 
avertable mortality from NCDs. Cardiovascular diseases, cancers, and chronic respiratory diseases have been the main 
drivers of the global and regional reduction in premature avertable mortality from NCDs, whereas premature mortality 
from substance use disorders, chronic kidney disease and acute glomerulonephritis, and diabetes have been increasing.
Interpretation Worldwide, there has been a substantial reduction in premature avertable mortality from NCDs, but 
progress has been uneven across populations. Countries vary substantially in current levels and trends and, 
hence, the extent to which they are on track to achieve SDG 3.4. By accounting for premature avertable mortality while 
avoiding arbitrary age cutoffs, premature avertable mortality from NCDs is a robust, comprehensive, and actionable 
indicator for quantifying and monitoring global and national progress towards NCD prevention and control.
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Introduction
In response to resolutions made at the 2011 UN High-
Level Meeting on non-communicable diseases (NCDs), 
the WHO Global Action Plan for the Prevention 
and Control of NCDs urges member states to reduce 
mor tality from four major NCDs (cardiovascular 
diseases, cancers, diabetes, and chronic respiratory 
diseases) among people aged 30–70 years by 25% 
between 2010 and 2025.1 Sustainable Development Goals 
(SDGs) target 3.4 aims to reduce mortality from NCDs 
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by one third by 2030 relative to its 2015 level.2 Both 
measure premature NCD mortality as the unconditional 
probability of dying aged 30–70 years from the 
aforementioned four NCDs. However, the exclusion of 
deaths at ages younger than 30 years and older than 
70 years or from NCDs other than the four major ones 
has been controversial.3–5 Many excluded NCD causes 
are amenable to prevention and treatment, and some 
NCD deaths among people aged 70 years and older 
can be postponed. Hence, the Lancet NCD Countdown 
2030 Collaborators5 and others4 have called for a more 
inclusive and comprehensive approach, better aligned 
with the WHO goal of “leaving no one behind”.
In response, we developed a new measure: years of 
life lost (YLLs) due to premature avertable mortality 
from NCDs (hereafter referred to as premature avertable 
mortality from NCDs). This measure combines a new list 
of all NCD mortality causes that are preventable through 
public policies and health programmes or are amenable 
to health care, with a calculation of YLLs due to premature 
mortality. Our approach draws on the notion of 
“unnecessary, untimely deaths”, introduced in the 1970s 
by Rutstein and colleagues,6 who proposed a list of causes 
from which death would not occur in the presence of 
timely and effective medical care. This concept—termed 
amenable mortality—was modified and extended, 
accounting for advances in medical care and improved 
knowledge of cause-specific epidemiology.7–9 It has been 
used in different populations,10–13 including countries of 
the EU and the Organisation for Economic Co-operation 
and Development, and in comparisons between states 
and health systems in the USA and European countries.12,13 
Other studies extended the set of amenable conditions to 
include ones targeted by public health programmes,13 
coining the concept of avoidable mortality. To date, the 
most widely cited list of causes amenable to health care is 
that of Nolte and McKee,14 which has been used extensively 
in countries belonging to the Organisation for Economic 
Co-operation and Development,12,13 and by the Global 
Burden of Diseases, Injuries, and Risk Factors Study 
(GBD) to create the Health Access and Quality Index.15 A 
study16 of mortality attributable to low-quality health 
systems extended this list to a total of 61 conditions for 
which the risk of death could be reduced by personal 
health care not requiring advanced technology. In our 
approach, avertable mortality refers to mortality that is 
avertable by public policies and health interventions to 
prevent the condition in the first place, as well as mortality 
that can be avoided or postponed by good quality personal 
health care (panel). We calculate YLLs with reference to 
standardised life expectancy at age of death, thus avoiding 
arbitrary age cutoffs.
We aimed to estimate premature avertable mortality 
from NCDs globally, regionally, and nationally by sex, 
age, location and year, examine trends from 1990 to 2017, 
assess progress towards SDG target 3.4, analyse the 
Research in context
Evidence before this study
We did not do a formal literature review. National and global 
progress towards the Sustainable Development Goal (SDG) 
target 3.4—a one-third reduction, relative to 2015 levels, in the 
probability of dying aged 30–70 years from any major 
non-communicable disease (NCD), including cancers, 
cardiovascular diseases, chronic respiratory diseases, and 
diabetes, by 2030—has been reported in other studies. 
However, the standard indicator is narrowly defined to include 
only four major NCDs and only for people aged 30−70 years. 
The NCD Countdown 2030 report proposed a more 
comprehensive indicator, but it still excludes people aged 
80 years and over. A comprehensive and actionable measure of 
premature mortality from NCDs is needed for the informed 
analysis of epidemiological trends, health system performance, 
and effect of policies.
Added value of this study
This study develops a new measure to quantify the premature 
avertable mortality from NCDs. It combines a novel list of NCD 
causes accounting for deaths preventable through public policies 
and population-based health interventions and amenable to 
health care, with a health gap measure: years of life lost (YLLs) 
due to premature mortality. It presents a trend analysis for 
premature avertable mortality from NCDs at global, regional, 
and national levels based on 2017 data from the Global Burden 
of Diseases, Injuries, and Risk Factors Study, and assesses 
progress towards SDG target 3.4, as measured by premature 
avertable mortality from NCDs. To our knowledge, this is the first 
study to apply a metric of premature avertable NCD mortality 
without arbitrary restrictions by age or disease category.
Implications of all the available evidence
This study describes levels and trends for premature 
avertable mortality from NCDs globally, for WHO regions, 
and 195 countries and territories from 1990 to 2017. Between 
1990 and 2017 premature avertable mortality from NCDs fell 
substantially worldwide, in all regions, and in all but 14 countries. 
Yet, only two WHO regions and 25 countries are on track to reach 
the SDG target 3.4. Most clusters of avertable NCDs contributed 
to the overall reduction in premature avertable mortality from 
NCDs. However, substance use disorders, chronic kidney disease 
and acute glomerulonephritis, and diabetes attenuated the 
overall reduction in many countries and regions. Globally in 
2017, 8423 years of life per 100 000 people were still lost to 
conditions that could be averted with effective policies and 
interventions. YLLs due to premature avertable NCD mortality 
should become a key indicator to shape policy and identify 
priorities for interventions.
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contribution of NCD clusters to overall trends, and 
discuss policy implications.
Methods
Estimation of premature avertable mortality
We reviewed lists of causes accounting for deaths 
considered to be either preventable by public policies and 
health programmes or amenable to good quality health 
care. These included lists developed by Nolte and 
McKee,13,14 Eurostat’s Working Group on Public Health 
Statistics,17 the Canadian Institute for Health Information 
and Statistics Canada,18 and the health ministries of 
Mexico, Brazil, and New Zealand.19–21 From this review, 
we created a new list of fatal and non-fatal conditions. We 
included conditions after evaluating evidence that 
deaths due to the corresponding cause can be averted in 
the presence of effective health care, public health 
interventions, or other policies. We mapped each cause 
category to the GBD cause list22 based on the International 
Classification of Diseases codes and created a list of 
90 causes (appendix 2 p 7). A few conditions from our list 
could not be mapped, usually because GBD includes 
them within larger groups of causes that are not 
considered avertable. Where GBD provides separate 
categories, we disaggregated our categories accordingly.
To quantify premature avertable mortality from NCDs, 
we considered eight disease clusters based on the 
avertable cause list (cardiovascular diseases, neoplasms 
[cancers], chronic respiratory diseases, digestive diseases, 
neurological disorders, substance use disorders, diabetes 
and chronic kidney disease, and other NCDs) covering 
43 fatal conditions (table 1). For comparison, causes of 
non-avertable mortality from NCDs are given in table 2. 
Rather than impose arbitrary age limits, we used a widely 
used health gap metric—YLLs due to premature 
mortality—derived from the standard life expectancy at 
each age.
Our analysis draws on GBD 2017 estimates.23,24 The 
GBD study is a multinational research collaboration 
designed to produce consistent and comparable estimates 
of health effects related to more than 328 diseases and 
injuries in 195 countries and territories. Its methods have 
been described previously23,24 and are summarised in 
appendix 2 (p 10).
YLLs measure premature death, calculated as the sum 
of each death observed at each specific age in a certain 
year multiplied by the standard life expectancy at each 
age, estimated from life tables.25 Standard life expectancy 
was taken from the lowest observed risk of death for each 
5-year age group in all populations greater than 5 million 
(appendix 2 p 14). GBD 2017 includes new assessments 
of population, fertility, migration, and all-cause 
mortality.26 These components were used to generate 
population estimates by age, sex, and year.
We extracted estimates of numbers of deaths and 
YLLs, with 95% uncertainty intervals (UIs), for every 
cause of death from the GBD cause list, by sex, age 
group, location (global, six WHO regions, and 
195 countries and territories [appendix 2 p 17]), and 
annually from 1990 to 2017 using the GBD Results Tool. 
We used GBD 2017 population estimates by sex, age, 
location, and year from 1990 to 2017,27 which we extracted 
from the Global Health Data Exchange.27
We estimated age-standardised YLL per 100 000 pop-
ulation with 95% UIs for all avertable deaths from 
NCDs, and clusters thereof, for non-avertable NCD 
deaths and all-NCDs deaths by sex, location, and year. 
First, we computed the number of deaths and YLLs by 
sex, age group, location, and year from each category of 
causes by aggregating separately the number of deaths 
and the number of YLLs, based on the cause list of 
avertable NCD mortality (table 1). Second, we calculated 
age-specific and sex-specific YLLs per 100 000 population 
for each cause group (avertable NCDs, avertable NCD 
clusters, non-avertable NCDs, and all NCDs) by location 
for 1990–2017. Third, we calculated age-standardised 
YLL per 100 000 population by cause, sex, location, and 
year by direct method using the world standard 
population,28 as shown in appendix 2 (p 16). We 
computed the 95% UIs for age-specific and sex-specific 
YLL and age-standardised YLL by propagating the 
uncertainty from the GBD estimates of YLLs and 
population (appendix 2 p 12).
Assessment of trends from 1990 to 2017
We did Joinpoint regression analysis29 to assess 
trends in premature avertable mortality from NCDs, for 
each NCD cluster, and for non-avoidable NCDs for 
1990–2017. We estimated inflexion points (joinpoints) 
from trends and the average (mean) annual percentage 
change (AAPC) by regressing a log-linear function of 
For the GBD Results Tool see 
http://ghdx.healthdata.org/gbd-
results-tool?params=gbd-api-
2017-permalink/15af25bc634e7
e0514f7fb287db5085e
See Online for appendix 2
Panel: Key concepts and terminology
Here we present some concepts and terminology used in this Article, which are frequently 
used in the literature focused on assessing public health interventions and health-care 
quality, and the Global Burden of Diseases, Injuries, and Risk Factors Study.
Avertable mortality refers to mortality from diseases where death could be prevented in 
the presence of effective health policies and population-based interventions, in addition 
to mortality that can be avoided or postponed in the presence of access to high-quality 
personal health care once the condition occurs.
Preventable mortality refers to disease mortality that can be avoided through public 
health programmes or policies focused on wider determinants of health, such as 
behavioural, biological, and environmental risk factors, and socioeconomic status.9,10
Amenable mortality refers to mortality from diseases where death can be avoided or 
postponed by high-quality personal health care.9,10
With some conditions, premature mortality can be reduced by both personal health care 
and public health programmes and policies.14
For this study, we use the concept of avertable mortality to quantify the levels of 
premature avertable mortality from non-communicable diseases. This study does not 
differentiate between preventable and amenable mortality from such diseases.
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ICD-10 ICD-9
Neoplasms
Lip and oral cavity cancer C00–C08·9, D10·0–D10·5, D11–D11·9, Z85·81–Z85·810 140–145·9, 210·0–210·6, 235·0, V76·42
Nasopharynx cancer C11–C11·9, D10·6 147–147·9, 210·7–210·9
Other pharynx cancer C09–C10·9, C12–C13·9, D10·7 146–146·9, 148–148·9
Oesophageal cancer C15–C15·9, D00·1, D13·0, Z85·01 150–150·9, 211·0, 230·1
Stomach cancer C16–C16·9, D00·2, D13·1, D37·1, Z12·0, Z85·02–Z85·028 151–151·9, 211·1, 230·2, 209·23, V10·04
Colon and rectum cancer C18–C21·9, D01·0–D01·3, D12–D12·9, D37·3–D37·5 153–154·9, 209·1–209·17, 209·5–209·57, 211·3–211·4, 230·3–230·6
Liver cancer C22–C22·9, D13·4 155–155·9, 211·5
Larynx cancer C32–C32·9, D02·0, D14·1, D38·0, Z85·21 161–161·9, 212·1, 231·0, 235·6, V10·21
Tracheal, bronchus, and lung 
cancer
C33–C34·9, D02·1–D02·3, D14·2–D14·3, D38·1, Z12·2, Z80·1–Z80·2, 
Z85·1–Z85·20
162–162·9, 212·2–212·3, 231·1–231·2, 235·7, 209·21, V10·1–V10·20, V16·1–V16·2, 
V16·4–V16·40
Malignant skin melanoma C43–C43·9, D03–D03·9, D22–D23·9, D48·5, Z85·82–Z85·828 172–172·9
Non-melanoma skin cancer 
(squamous-cell carcinoma)
C44–C44·99, D04–D04·9, D49·2 173–173·99, 222·4, 232–232·9, 238·2
Breast cancer C50–C50·929, D05–D05·92, D24–D24·9, D48·6–D48·62, D49·3, N60–N60·99 174–175·9, 217–217·8, 233·0, 238·3, 239·3, 610–610·9
Cervical cancer C53–C53·9, D06–D06·9, D26·0 180–180·9, 219·0, 233·1
Uterine cancer C54–C54·9, D07·0–D07·2, N87–N87·9 182–182·8, 233·2
Testicular cancer C62–C62·92, D29·2–D29·8, D40·1–D40·8 186–186·9, 222·0, 222·3, 236·4
Bladder cancer C67–C67·9, D09·0, D30·3, D41·4–D41·8, D49·4 188–188·9, 223·3, 233·7, 236·7, 239·4
Thyroid cancer C73–C73·9, D09·3, D09·8, D34–D34·9, D44·0, Z85·850 193–193·9, 226–226·9
Mesothelioma C45–C45·9 ··
Hodgkin lymphoma C81–C81·99 201–201·98
Leukaemia C91–C95·92 204–208·92
Cardiovascular diseases
Rheumatic heart disease I01–I01·9, I02·0, I05–I09·9 391–391·9, 392·0, 393–398·99
Ischaemic heart disease I20–I25·9 410–414·9
Cerebrovascular disease G45–G46·8, I60–I61·9, I62·0–I62·03, I63–I63·9, I65–I66·9, I67·0–I67·3, 
I67·5–I67·6, I68·1–I68·2, I69·0–I69·398
430–435·9, 437·0–437·2, 437·5–437·8
Hypertensive heart disease I11–I11·9 402–402·91
Alcoholic cardiomyopathy I42·6 425·5
Aortic aneurysm I71–I71·9 441–441·9
Chronic respiratory diseases
Classifications D86–D86·2, D86·89–D86·9, G47·3–G47·39, J30–J35·9, J37–J47·9, 
J60–J63·8, J65–J68·9, J70–J70·1, J70·8–J70·9, J82, J84–J84·9, J91–J92·9
135–135·9, 136·6, 327·2–327·8, 470, 470·9–474·9, 476–476·1, 477–479, 490–504·9, 
506–506·9, 508–509, 515, 516–517·8, 518·6, 518·9, 519·1–519·4, 780·57, 786·03
Digestive diseases
Cirrhosis and other chronic liver 
diseases due to hepatitis B
B18·0, B18·1 702–703
Cirrhosis and other chronic liver 
diseases due to hepatitis C
B18·2 704–705
Cirrhosis and other chronic liver 
diseases due to alcohol use
K70·0–K70·3 571·0–571·2
Peptic ulcer disease K25–K28·9, K31, K31·1–K31·6, K31·8, K31·82–K31·89 531–534·91
Appendicitis K35–K37·9, K38·3–K38·9 540–542·9
Inguinal, femoral, and 
abdominal hernia
K40–K42·9, K44–K46·9 550–551·1, 551·3–552·1, 552·3–553·03, 553·6
Gallbladder and biliary diseases K80–K83·9, K87–K87·1 574–576·9
Pancreatitis K85–K86·9 577–577·9, 579·4
Neurological disorders
Alzheimer’s disease and other 
dementias
F00–F03·9, G30–G31·1, G31·8–G31·9 290–290·9, 294·1–294·9, 331–331·2
Epilepsy G40–G41·9 345–345·91
Substance use disorders
Alcohol use disorders F10–F10·9, G31·2, G72·1, P04·3, Q86·0, R78·0, X45–X45·9, X65–X65·9, 
Y15–Y15·9
291–291·9, 303–303·9, 305·0, 357·5, 790·3, E860
Drug use disorders F11–F16·9, F18–F19·9, P04·4, P96·1, R78·1–R78·5 292–292·9, 304·0–304·8, 305, 305·1–305·9, 760·7, E850
(Table 1 continues on next page)
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ICD-10 ICD-9
(Continued from previous page)
Diabetes, urogenital, blood, and endocrine diseases
Diabetes E10–E10·11, E10·3–E11·1, E11·3–E12·1, E12·3–E13·11, E13·3–E14·1, 
E14·3–E14·9, P70·0–P70·2, R73–R73·9
250–250·39, 250·5–250·99, 357·2, 775·0–775·1, 790·2–790·22
Acute glomerulonephritis N00–N01·9 580–580·9
Chronic kidney disease D63·1, E10·2–E10·29, E11·2–E11·29, E12·2, E13·2–E13·29, E14·2, I12–I13·9, 
N02–N08·8, N15·0, N18–N18·9
250·4–250·49, 403–404·93, 581–583·9, 585–585·9, 589–589·9
Other non-communicable diseases
Congenital birth defects P96·0, Q00–Q07·9, Q10·4–Q18·9, Q20–Q28·9, Q30–Q36, Q37–Q45·9, 
Q50–Q60·6, Q63–Q86, Q86·1–Q87·8, Q89–Q89·8, Q90–Q93·9, Q95–Q99·8
740–749·0, 749·2–752·9, 753·4–758·9, 759·0–759·8
ICD=International Statistical Classification of Diseases and Related Health Problems.
Table 1: Causes of avertable mortality from non-communicable diseases
ICD-10 ICD-9
Neoplasms
Nasopharynx cancer C11–C11·9, D10·6 147–147·9, 210·7–210·9
Others pharynx cancer C09–C10·9, C12–C13·9, D10·7 146–146·9, 148–148·9
Gallbladder and biliary tract cancer C23–C24·9, D13·5 156–156·9
Pancreatic cancer C25–C25·9, D13·6–D13·7 157–157·9, 211·6–211·7
Ovarian cancer C56–C56·9, D27–D27·9, D39·1 183–183·0, 220–220·9, 236·2
Prostate cancer C61–C61·9, D07·5, D29·1, D40·0 185–185·9, 222·2, 236·5
Kidney cancer C64–C65·9, D30·0–D30·1, D41·0–D41·1 189·0–189·1, 189·5–189·6, 223·0–223·1
Brain and nervous system cancer C70–C72·9 191–192·9
Non-Hodgkin lymphoma C82–C86·6, C96–C96·9 200–200·9, 202–202·9
Multiple myeloma C88–C90·9 203–203·9
Other malignant neoplasms C17–C17·9, C30–C31·9, C37–C38·8, C40–C41·9, C47–C4A, C51–C52·9, 
C57–C57·8, C58–C58·0, C60–C60·9, C63–C63·8, C66–C66·9, C68·0–C68·8, 
C69–C69·9, C74–C75·8, D07·4, D09·2, D13·2–D13·3, D14·0, D15–D16·9, 
D28·0–D28·1, D28·7, D29·0, D30·2, D30·4–D30·8, D31–D31·9, D35–D35·2, 
D35·5–D36, D36·1–D36·7, D37·2, D38·2–D38·5, D39·2, D39·8, D41·2–D41·3, 
D44·1–D44·8, D48·0–D48·4
152–152·9, 158–158·9, 160–160·9, 163–164·9, 170–171·9, 181–181·9, 
183·2–183·8, 184·0–184·4, 184·8, 187·1–187·8, 189·2–189·4, 189·8, 
190–190·9, 194–194·8, 209·0, 209·4, 211·2, 211·8, 212·0, 212·4–212·8, 
213–213·9, 221·0–221·8, 222·1, 222·8, 223·2, 223·8, 224–224·9, 
227–228·9, 229·0, 229·8, 230·7–230·8, 233·4–233·5, 234·0–234·8, 235·4, 
235·8, 236·1, 238·0–238·1, 239·2
Other neoplasms D32–D33·9, D35·3–D35·4, D42–D43·9, D45–D47·9, D49·6, K62·0–K62·1, 
K63·5, N60–N60·9, N84·0–N84·1, N87–N87·9
225–225·9, 237–237·3, 237·5–237·9, 238·4–238·9, 239·6
Cardiovascular diseases
Non-rheumatic valvular heart 
disease
I34–I37·8 424·0–424·3, 424·8
Myocarditis B33·2, I40–I41·9, I51·4 422–422·9
Other cardiomyopathy I42·1–I42·5, I42·7–I42·8, I43–I43·9 425·0–425·3, 425·7–425·8, 429·0
Atrial fibrillation and flutter I48–I48·9 427·3
Peripheral artery disease I70·2–I70·8, I73–I73·9 440·2, 440·4, 443·0–443·9
Endocarditis I33–I33·9, I38–I39·9 421–421·9, 424·4–424·5, 424·9
Other cardiovascular and circulatory 
diseases
I28–I28·8, I30–I31·1, I31·8–I32·8, I47–I47·9, I51·0–I51·3, I68·0, I72–I72·9, 
I77–I83·9, I86–I89·0, I89·9, I98, K75·1
036·4, 417–417·9, 420–420·9, 423, 423·1–423·9, 427–427·2, 427·6–427·8, 
442–443, 447–454·9, 456, 456·3–457, 457·1, 457·8–457·9, 459, 459·1–459·3
Digestive diseases
Cirrhosis due to non-alcoholic 
steatohepatitis
K75·81 573·8
Cirrhosis and other chronic liver 
diseases due to other causes
B18·8–B18·9, K71·7, K73, K75·2–K75·8, K75·89, K75·9, 
K76·1–K76·2, K76·4–K76·9, K77·8
571·4–571·9, K72·2, 573·0, 573·4, 573·9 
Gastritis and duodenitis K29–K29·9 535–535·9
Paralytic ileus and intestinal 
obstruction
K56–K56·9 560–560·3, 560·8–560·9
Inflammatory bowel disease K50–K52·9, M09·1 555–556·9, 558–558·9, 569·5
Vascular intestinal disorders K55–K55·9 557–557·9
(Table 2 continues on next page)
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age-standardised YLL per 100 000 population on year. 
We configured the model to detect a maximum of 
five joinpoints and avoid segments comprising only 
two datapoints. We calculated AAPCs and 95% UI 
for 1990–2017 and subperiods (1990–99, 2000–09, and 
2010–17), by sex (male, female, and both) at global, 
regional, and country levels. The AAPC is a summary 
measure of the trend over a prespecified fixed interval, 
computed as a weighted average (mean) of the annual 
percentage change of each time segment from the 
Joinpoint model, with weights equal to the length of 
each segment over time. We used the Monte Carlo 
method30 with 4499 randomly permuted datasets 
to calculate the 95% UIs of the AAPCs, and the 
overall asymptotic significance level was maintained 
through a Bonferroni correction. We assumed constant 
variance (homoscedasticity) in age-standardised YLL 
over time. However, these tests also consider situations 
with non-constant variance, Poisson variation, and 
possible autocorrelation errors. AAPC is considered 
significant when it is different from zero at α=0·05. A 
constant trend was considered when the zero value was 
within both 95% UI limits for the AAPC, an increasing 
trend when both 95% UI limits were positive, and a 
decreasing trend when both 95% UI limits were 
negative.
ICD-10 ICD-9
(Continued from previous page)
Other digestive diseases I84–I84·9, K20–K20·9, K22–K22·6, K22·8–K24, K31·0, K31·7, K38–K38·2, 
K57–K62, K62·2–K62·6, K62·8–K62·9, K64–K64·9, K66·8, K67, K68–K68·9, 
K77, K90–K90·9, K92·8, K93·8
455–455·9, 530–530·0, 530·2–530·7, 530·9, 536–536·1, 537–537·6, 537·8, 
538, 543–543·9, 553·1–553·3, 562–562·1, 564–564·1, 564·5–564·7, 
565–566·9, 569·1–569·4, 569·7, 579–579·2, 579·8–579·9
Neurological disorders
Parkinson’s disease G20–G20·9 332–332·0
Multiple sclerosis G35–G35·9 340–340·9
Motor neuron disease G12·2–G12·9 335–335·2, 335·8–335·9
Other neurological disorders G10–G12·1, G13–G13·8, G23–G24, G24·1–G25·0, G25·2–G25·3, G25·5, 
G25·8–G26·0, G36–G37·9, G61–G61·9, G70–G72, G72·2–G73·7, G90–G90·9, 
G95–G95·9, M33–M33·9
330–330·9, 331·5–331·9, 333–334·9, 335·3, 336–337·9, 341–341·9, 349, 
349·2–349·8, 353·6–353·9, 356–356·9, 357·0–357·1, 357·3–357·4, 357·7, 
358–359·9, 775·2
Mental disorders
Eating disorders F50·0–F50·5 307·1
Skin and subcutaneous diseases
Bacterial skin diseases A46–A46·0, A66–A67·9, I89·1–I89·8, L00–L05·9, L08–L08·9, L88, 
L97–L98·4, M72·5–M72·6
035–035·9, 102–103·9, 457·2–457·3, 680–689
Decubitus ulcer L89–L89·9 707–707·9
Other skin and subcutaneous 
diseases
D86·3, L10–L14·0, L51–L51·9 694–695·3
Musculoskeletal disorders
Rheumatoid arthritis M05–M06·9, M08·0–M08·8 714–714·3, 714·8–714·9
Other musculoskeletal disorders I27·1, I67·7, L93–L93·2, M00–M03·0, M03·2–M03·6, M07–M08, 
M08·9–M09·0, M09·2–M09·8, M30–M32·9, M34–M36·8, M40–M43·1, 
M65–M65·0, M71·0–M71·1, M80–M82·8, M86·3–M86·4, M87–M87·0, 
M88–M89·0, M89·5, M89·7–M89·9
416·1, 437·4, 446–446·9, 695·4–695·5, 710–711·9, 730·1, 732–732·9, 
733·0–733·1
Other non-communicable diseases
Urinary tract infections N10–N12·9, N15, N15·1–N16·8, N30–N30·9, N34–N34·3, N39·0–N39·2 590–590·9, 595–595·9, 597–597·9, 599·0
Urolithiasis N20–N23·0 592–592·9, 594–594·9, 788·0
Other urinary diseases N25–N28·1, N29–N29·8, N31–N32·0, N32·3–N32·4, N36–N36·9, N39, 
N41–N41·9, N44–N44·0, N45–N45·9, N49–N49·9
588–588·9, 593–593·8, 596–596·9, 598–598·1, 598·8–599, 
599·1–599·6, 599·8, 601–602·9, 604–604·9, 608·2
Gynaecological diseases D25–D26, D28·2, E28·2, N72–N72·0, N75–N77·8, N80–N81·9, N83–N83·9 218–219, 219·1–219·9, 236·0, 256·4, 617–618·9, 620–620·9, 
621·4–621·9, 622·3–622·6, 629–629·8
Haemoglobinopathies and 
haemolytic anaemias
D55–D58·9, D59·1, D59·3, D59·5, D60–D61·9, D64·0 282–284·9
Endocrine, metabolic, blood, and 
immune disorders
D52·1, D59·0, D59·2, D59·6, D66–D67, D68·0–D69·8, D70–D75·8, D76–D78·8, 
D86·8, D89–D89·3, E03–E07·1, E09–E09·9, E15·0, E16·0–E16·9, E20–E28·1, 
E28·3–E34·8, E36–E36·8, E65–E68, E70–E85·2, E88–E89·9, G24·0, G25·1, 
G25·4, G25·6–G25·7, G72·0, G93·7, G97–G97·9, I95·2–I95·3, I97–I97·9, I98·9, 
J70·0–J70·5, J95–J95·9, K43–K43·9, K62·7, K91–K91·9, K94–K95·8, M87·1, 
N14–N14·4, N65–N65·1, N99–N99·9, P96·2, P96·5, R50·2
240–243·9, 244·0–244·1, 244·3–244·8, 245–246·9, 251–256·3, 
256·8–259·9, 270–273·9, 275–276, 277–277·2, 277·4–277·9, 278·0–278·8, 
286–286·5, 286·7–289·7, 357·6, 518·7, 519·0, 536·4, 539–539·9, 551·2, 
552·2, 564·2–564·4, 569·6, 579·3, 598·2, 775·3, 779·4–779·5
Sudden infant death syndrome R95–R95·9 798–798·0
ICD=International Statistical Classification of Diseases and Related Health Problems.
Table 2: Causes of non-avertable mortality from non-communicable diseases
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Assessment of progress towards SDG target 3.4
We assessed progress towards SDG target 3.4 by 
estimating AAPC and 95% UI for 2010–17. Countries 
were considered on track if the upper 95% UI of the 
AAPC was –2·22% or lower (equivalent to a one-third 
reduction by 2030 relative to 2015 levels). Countries 
whose lower and upper 95% UI for AAPC exceeded 
–2·22% were categorised as progressing with a high 
chance of reaching the target. Countries with lower and 
upper 95% UIs of AAPC between –2·22% and 0% 
were categorised as progressing, but not on track. 
Countries in which the upper 95% UI of the AAPC 
was 0 or above were categorised as stagnating or 
deteriorating.
We did a decomposition analysis31 of AAPC for 
premature avertable mortality from NCDs and NCD 
clusters by location and sex for 2010–17 to determine 
which causes of death drove overall trends. We 
calculated the change in premature avertable mortality 
from NCDs for each disease cluster using counterfactual 
scenarios: allowing premature avertable mortality from 
NCDs for each disease cluster to change as they did 
from 2010 to 2017, while keeping premature mortality 
constant at 2010 levels for other causes. We then 
calculated the fraction of change for each disease 
cluster relative to the sum of change of all nine clusters, 
and multiplied this fraction by the AAPC for all 
premature avertable mortality from NCDs—ie, making 
Figure 1: Global deaths by broad group of causes (A) and avertable and non-avertable deaths due to non-communicable diseases (B) by age group and sex, 2017
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the fraction of change proportional to the rate of the 
change that would occur if each disease cluster alone 
had changed.
This analysis adheres to the Guidelines for Accurate 
and Transparent Health Estimates Reporting standards32 
developed by WHO and others (appendix 2 p 52).
Role of the funding source
No funding was received for this study. The corresponding 
author had full access to all the data in the study and had 
final responsibility for the decision to submit for 
publication.
Results
Globally, NCDs accounted for an estimated 41·1 million 
(95% UI 40·4–41·5) deaths in 2017, representing 73·5% 
(70·8–75·7) of all deaths. They caused a small proportion 
of deaths in childhood, but their share of all deaths 
increased rapidly with age until about 60 years, when the 
proportion plateaued at over 80% (figure 1A). Avertable 
NCDs accounted for the largest share of these deaths, 
34·5 million (95% UI 33·4–35·6), or 83·9% (80·4–88·1) of 
all NCD deaths worldwide. In all age groups, more than 
50% of NCD deaths are avertable, with the share increasing 
with age once individuals are older than 5 years (figure 1B).
The number of avertable global NCD deaths increased 
by 49·3% (95% UI 47·3 to 52·2) from 23·1 million 
(22·0 to 24·1) deaths in 1990 to 34·5 million (33·4 to 35·6) 
in 2017. Global age-standardised YLL per 100 000 population 
due to avertable NCDs declined substantially for both 
sexes combined, at an average (mean) annual rate of 
–1·3% (95% UI –1·4 to –1·2) from 12 885 years (95% UI 
11 809 to 14 051) in 1990 to 9008 years (8329–9756) 
in 2017 (figure 2). In 2017, premature avertable mortality 
from NCDs was more than four times the rate for non-
avertable NCDs, both globally (–0·5% [95% UI 
–0·6 to –0·5]) and for every WHO region.
For men, global premature avertable mortality from 
NCDs declined by –1·2% (95% UI –1·4 to –1·0) per year 
from 14 092 years (12 981 to 15 375) in 1990 to 10 187 years 
(9318 to 11 132) in 2017. It declined slightly faster among 
women, with an AAPC of –1·4% (95% UI –1·5 to –1·3), 
from 9997 years (8902 to 11 064) in 1990 to 6811 years 
(6186 to 7510) in 2017. However, this difference between 
sexes is not significant (appendix 2 pp 27–33).
This decline in global premature avertable mortality 
from NCDs changed over time in five segments: 
beginning slowly in 1990−94 (–0·27%), accelerating in 
1994−2003 (–1·5%), further accelerating in 2003−07 
(–2·26%), but decelerating in 2007−13 (–1·33%) and 
2013−17 (–0·72%), when there were significant reductions 
(appendix 2 p 18). Trends were similar for both sexes.
Between 1990 and 2017, premature avertable mortality 
from NCDs fell substantially in every WHO region, with 
Figure 2: Global and regional trends in age-standardised YLL lost due to premature avertable and non-avertable mortality from NCDs, 1990–2017
(A) Avertable and non-avertable mortality from NCDs. Red=premature avertable mortality from NCDs. Blue=premature non-avertable mortality from NCDs. (B) Avertable mortality from NCDs. 
AAPC=average (mean) annual percentage change. NCDs=non-communicable diseases. YLL=years of life lost. 
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AAPC ranging from –1·7 (95% UI –2·0 to –1·5) in 
the Western Pacific region to –0·9% (–1·0 to –0·8) in 
the Eastern Mediterranean region (figure 2). As with the 
global picture, these reductions were substantially higher 
for avertable than for non-avertable mortality from 
NCDs. In 2017, premature avertable mortality from 
NCDs was highest in the Eastern Mediterranean, 
followed by South-East Asia, and African regions with 
Figure 3: Level and trends in 
premature avertable 
mortality from 
non-communicable diseases
(A) Age-standardised YLL due 
to premature avertable 
mortality from NCDs for both 
sexes combined in 2017. 
Countries are colour coded on 
the basis of quintiles of the 
age-standardised YLL rates due 
to premature avertable 
mortality from NCDs. 
(B) AAPC in age-standardised 
YLL due to premature 
avertable mortality from 
non-communicable diseases 
for both sexes combined, 
2010−17. Countries are colour 
coded by level of progress 
towards SDG target 3.4, as 
described in the Methods. 
Appendix 2 includes the 
distribution by sex (pp 34, 43) 
and numerical values (p 24). 
NCDs=non-communicable 
diseases. SDG=Sustainable 
Development Goal. 
AAPC=Average (mean) annual 
percentage of change. 
UI=uncertainty intervals.
YLL=years of life lost.
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levels over those observed globally (figure 2). Since 2013, 
premature non-avertable mortality from NCDs decreased 
slightly or stagnated in most regions, and rose in the 
Region of the Americas.
78 (40%) of 195 countries with high levels of premature 
avertable mortality from NCDs (over 10 022·9 years per 
100 000 population) are low-income and middle-income 
countries in the South-East Asia, Eastern Mediterranean, 
and African regions (figure 3A). In 2017, premature 
avertable mortality from NCDs for both sexes combined 
was below 6130 years per 100 000 population in 
41 countries, mostly high-income economies (36 of 41) 
(figure 3A). Premature avertable mortality from NCDs by 
sex in 2017 is shown in appendix 2 (pp 34–39). The ten 
countries of more than 2 million people with the highest 
levels of premature avertable mortality from NCDs (all 
>18 300 years per 100 000 population) were Afghanistan, 
the Central African Republic, Uzbekistan, Haiti, 
Mongolia, Turkmenistan, Pakistan, Ukraine, Laos, and 
Egypt. Singapore, Japan, Switzerland, Italy, and Israel had 
the lowest levels of premature avertable mortality from 
NCDs, with values below 4000 years per 100 000 population 
(appendix 2 pp 37–39).
Premature avertable mortality from NCDs fell in most 
countries between 1990 and 2017, with 14 exceptions 
(appendix 2 pp 24–33, pp 40–42). 163 (84%) of 195 countries 
had significant reductions in the AAPC for premature 
avertable mortality from NCDs between 2010 and 2017 
(AAPC upper 95% UI ≤0%). However, only 25 countries 
had rates of decline significantly lower than –2·22% (ie, the 
required rate to be on track for achieving SDG target 3.4) 
for both sexes combined. Sex-disaggregated data are shown 
in appendix 2 (pp 43–48).
Figure 4 compares premature avertable mortality from 
NCDs in 2017 with the AAPC for 1990–2017 (figure 4A) 
and 2010−17 (figure 4B). Countries with fast declines 
in age-standardised YLL between 1990 and 2017 had low 
premature avertable mortality from NCDs by sex in 2017 
(figure 4A). In countries with high premature avertable 
mortality from NCDs in 2017 (>67th percentile) the pace 
of reduction accelerated between 2010 and 2017 in both 
sexes combined and in each sex (figure 4B). However, 
Ukraine, Libya, and Nepal are the top three countries 
with both high rates of premature avertable mortality 
from NCDs in 2017 and an increasing trend in 2010−17 in 
both sexes combined (figure 4B).
Figure 5 shows the contributions of NCD clusters to 
overall trends in premature avertable mortality from 
NCDs between 2010 and 2017 by sex and region. Data by 
sex and country are given in appendix 2 (pp 49–51). 
Globally, for both sexes combined, all clusters (except 
diabetes and substance use disorders) contributed to the 
reduction in premature avertable mortality from NCDs 
(figure 5). Cardiovascular diseases, cancer, chronic 
respiratory dis eases, congenital birth defects, and digestive 
diseases are the largest contributors, accounting for more 
than 80% of the overall decline. By contrast, substance use 
disorders slightly offset the decline in most of the regions, 
except the Americas. In the Americas, substance abuse 
disorders accounted for a 6% increase in the annual rate 
of change. The Western Pacific and European regions are 
the only two regions that are on track for reaching SDG 
target 3.4, assuming sustained progress until 2030.
A comprehensive set of estimates and interactive 
visualisations from this study are available online via the 
premature avertable mortality NCD Results Tool.
Discussion
To our knowledge, this is the first study that thoroughly 
assesses NCD mortality without arbitrary restrictions by 
age or disease category. Premature avertable mortality 
from NCDs shows the YLLs that could be averted if 
NCD risk factor exposures of populations were reduced 
to a theoretical minimum level and good quality health 
care was universally available. The high variation in 
premature avertable mortality from NCDs across 
countries in 2017 (range: 3421–28 490) indicates that 
levels in many countries can be considered excessively 
high. As such, we consider premature avertable 
mortality from NCDs to be a robust, compre hensive, 
Figure 4: ASYLL due to premature avertable mortality from NCDs in 2017 versus AAPC in 1990−2017 (A) and 
2010−17 (B)
Horizontal lines are the upper (67%) and lower (33%) terciles in age-standardised YLL due to premature avertable 
mortality from NCDs. Vertical lines represent the one-third reduction in AAPC by 2030, equivalent to –2·22%, and 
constant trend (zero value). Countries are colour coded according to nine quadrants created by the combination of 
age-standardised YLL rate terciles and AAPC cutoffs (–2·22% and 0). ASYLL=age-standardised years of life lost. 
AAPC=average (mean) annual percentage change. NCDs=non-communicable diseases.
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and actionable indicator for assessing performance in 
reducing NCD mortality and a powerful concept for 
informing public health and policy. For these reasons, 
and in the light of known concerns about the existing 
indicator set out by the Lancet NCD Countdown 2030 
Collaborators5 and others,4 we argue that it should be 
adopted as the gold standard.
Our study includes two important innovations. First, 
we review, update, and apply a new list of avertable 
burden conditions, which is exhaustive, comprehensive, 
and globally applicable. Second, we decompose overall 
changes in premature avertable mortality from NCDs by 
NCD clusters, going beyond the four NCD clusters 
(cancer, cardiovascular diseases, respiratory disease, and 
all other NCDs) used by the NCD Countdown 2030 
report5 to include eight clusters that account for avertable 
mortality. This approach allows for the identification of 
causes contributing to change in premature avertable 
mortality from NCDs.
WHO regions represent a heterogeneous set of 
countries and their overall epidemiological profiles are 
strongly shaped by the most populous countries. For 
example, the reduction in premature avertable mortality 
from NCDs in the Western Pacific region is largely due to 
the rapid decline achieved by China.33 Similarly, the early 
1990s spike in such mortality in the European region is 
mainly driven by trends in formerly socialist economies 
in eastern Europe.34 The deceleration in the decline and 
subsequent reversal in this measure in the Americas 
since 2013 is explained by the notable increase in 
premature mortality from substance use disorders in 
the USA (appendix 2 pp 49–51).35
Notably, the Eastern Mediterranean region—the worst 
performing region in terms of premature avertable 
mortality from NCDs—is facing numerous health 
challenges related to armed conflicts and political 
crises.36 However, this is a descriptive study, which is not 
intended to assess the effects of specific public policies, 
inter ventions, or changing national circumstances. 
Interpretation of these trends in premature avertable 
mortality from NCDs should be done with great caution. 
For example, it is important to assess the relative 
contributions of NCD incidence and survival rates. 
Mortality attributable to premature avertable mortality 
from NCDs will be affected by competition from deaths 
from non-NCD causes, especially those at young ages, 
which is a particular concern in conflict situations. 
There might also be time lags between the reduction of 
amenable mortality and the introduction of interventions 
and policies. There is a need for more nuanced analysis 
of these effects in future studies of premature avertable 
mortality from NCDs.
Despite the global reduction in premature avertable 
mortality from NCDs, our analysis showed that only the 
Western Pacific and European regions and 25 countries 
(mostly high-income economies) are on track to achieve 
SDG target 3.4. This finding is consistent with values 
reported by NCD Countdown 2030,5 and raises concerns 
about the global community’s ability to meet the SDG 
commitments. Worldwide in 2017, 9008 years of life per 
100 000 population were lost due to conditions amenable to 
effective public policies, health interventions, and health 
care. This global level is almost three times the best 
performing countries (3421 YLLs per 100 000 population), 
showing what can theoretically be achieved. 65 countries 
had what can be considered high levels of premature 
avertable mortality from NCDs in 2017 (over the upper 
tercile of the distribution by country, equivalent to 
10 712 YLL per 100 000 population), the most populous 
examples being Afghanistan, the Central African Republic, 
Uzbekistan, Haiti, Mongolia, Turkmenistan, Pakistan, 
Ukraine, Laos, and Egypt. Some countries, including 
Ukraine, Libya, and Nepal, present both high rates of pre-
mature avertable mortality from NCDs and an increasing 
trend since 2010.
Most NCD clusters have contributed to the overall 
reduction in premature avertable mortality from NCDs, 
Figure 5: Contributions of NCD clusters to the overall AAPC in the age-standardised YLL due to premature 
avertable mortality from NCDs by sex and region, 2010−17
The black dot shows the overall AAPC in the age-standardised YLL due to premature avertable mortality from NCDs 
for 2010−17. Bars show the contribution to change due to constituent NCD clusters, calculated so that their net effect 
equals the overall AAPC. Vertical lines represent the one-third reduction in AAPC by 2030, equivalent to –2·22%, and 
constant trend (zero value). Contributions of avertable NCD clusters to the overall AAPC in age-standardised YLL due 
to premature avertable mortality from NCDs by sex and country are in appendix 2 (pp 49–51). AAPC=average (mean) 
annual percentage change. YLL=years of life lost. NCDs=non-communicable diseases.
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but substance use disorders, chronic kidney disease and 
acute glomerulonephritis, and diabetes counteract this 
reduction in many countries and regions. Of these 
diseases, only diabetes is included as one of the four 
major NCDs promoted by global targets. Substance use 
disorders is an emerging and complex public health 
issue, now referred to as one of the so-called diseases of 
despair, which is especially marked in parts of the USA35 
and is an emerging concern for other countries, such as 
the UK.
Our approach has limitations associated with the use 
of GBD data,23,24,26 especially when high-quality vital 
registration systems are lacking, in terms of completeness, 
coverage, and medical certification, or complete absence 
of vital registration, and estimates are mostly based on 
modelling. Although the method used by the GBD study 
to estimate deaths and death rates by cause, the Cause 
of Death Ensemble model (CODEm), outperforms pre-
vious approaches, it is inevitably subject to problems in 
capturing data on the covariates used in CODEm, the 
treatment of outliers, and the rules used for redistribution 
of garbage codes.37 Nevertheless, the concept of YLL due 
to premature avertable mortality from NCDs offers a 
comprehensive and robust measure for monitoring NCD 
mortality. We used an alternative method to assess 
uncertainty to that applied by GBD. Although the point 
estimates of our comparison are identical to those derived 
from GBD methods, indicating that our comparison is 
valid, our method of assessing uncertainty is much more 
conservative than GBD (appendix 2 p 12). This difference 
is not surprising as the GBD method uses considerably 
more data. Our inferences based on the significance of 
differences between groups are also conservative, so we 
might have missed some significant findings (type 1 
error) that are detectable by GBD methods. Re-running 
our analyses using GBD methods for assessing un-
certainty would not result in any changes to the significant 
differences we have described, but might reveal further, 
smaller, differ ences that we would have rejected as non-
significant.
A one-third reduction of premature avertable mortality 
from NCDs by 2030 relative to its level in 2015 is a 
very ambitious goal, since it includes all preventable 
and treatable NCDs, and deaths at all ages. Measuring 
premature avertable mortality from NCDs allows for 
comparison of how countries succeed (or not) in pre-
venting and delaying deaths from conditions amenable 
to public health interventions and health care. This goal 
and measure should spur countries that are currently off 
track to re-evaluate and strengthen their action plans, 
including those for universal health care. Our study 
sounds an alarm about the global slowdown of the 
reduction in premature avertable mortality from NCDs 
since 2007—calling for more robust, politically committed 
responses to the social determinants of NCDs, effective 
public health interventions, and universal good quality 
health care for all.
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